Vol 9, No 2 (2018)
Review paper
Published online: 2018-08-17

open access

Page views 1215
Article views/downloads 1686
Get Citation

Connect on Social Media

Connect on Social Media

Polish experts’ opinion concerning brentuximab vedotin in treatament of primary cutaneous lymphomas with CD30 expression

Małgorzata Sokołowska-Wojdyło12, Jan Walewski31, Wiesław W. Jędrzejczak4, Tadeusz Robak5, Monika Prochorec-Sobieszek167, Jan Maciej Zaucha12, Alina Jankowska-Konsur18, Monika Słowińska9, Ewa Chmielowska110, Lidia Rudnicka11, Sebastian Giebel112
Hematologia 2018;9(2):83-89.

Abstract

The group of primary cutaneous T-cell lymphomas (CTCLs) expressing CD30 + is consisted of primary cutaneous anaplastic T-cell lymphoma (pcACTL), lymphomatoid papulosis (LyP), some cases of mycosis fungoides (MF) and Sezary syndrome (SS). It is well known that patient cannot be cured completely by available therapeutic methods. In addition, the effectiveness of available therapies is especially limited in advanced stages of the disease. Based on the results of the most recent trials, the experts recommend that brentuximab vedotin (BV) should be reimbursed in Poland for the treatment of adult patients with CTCL expressing CD30 who have had at least one prior systemic treatment. In case of MF BV should be preferred to bexarotene or MTX therapy due to the higher efficacy in stage IIB or higher. BV treatment should be also considered as an alternative to bexarotene (after ineffectiveness of local treatment, phototherapy and IFN/MTX therapy) in early stages of MF (IB-IIA).

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10): 3768–3785.
  2. Swerdlow SH, Campo E E, Harris N. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. IARC, Lyon 2017.
  3. Sokołowska-Wojdyło M, et al. Chłoniaki pierwotnie skórne — rekomendacje diagnostyczno-terapeutyczne Polskiego Towarzystwa Dermatologicznego Dermatol Rev/Przegl Dermatol. 2017; 104: 243–268.
  4. Sokołowska-Wojdyło M. Pierwotne chłoniaki skóry. In: Robak T, Warzocha K. ed. Hematologia. Via Medica, Gdańs 2016: 1042–1064.
  5. Sokołowska-Wojdyło M. Zasady postępowania w chłoniakach pierwotnie skórnych. In: Jędrzejczak WW, Robak T, Podolak-Dawidziak M. ed. Praktyka hematologiczna: praca zbiorowa. Termedia Wydawnictwa Medyczne, Poznań 2015: 271–284.
  6. Pimpinelli N, Olsen EA, Santucci M, et al. International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol. 2005; 53(6): 1053–1063.
  7. Thurber SE, Zhang B, Kim YH, et al. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol. 2007; 57(5): 782–790.
  8. Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009; 33(12): 1860–1868.
  9. Benner MF, Jansen PM, Vermeer MH, et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012; 119(7): 1643–1649.
  10. Kim YH, Tavallaee M, Sundram U, et al. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol. 2015; 33(32): 3750–3758.
  11. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015; 33(32): 3759–3765.
  12. Prince HM, Kim YH, Horwitz SM, et al. ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017; 390(10094): 555–566.
  13. Horwitz S, Whittaker S, Duvic M, et al. RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. Hematological Oncology. 2017; 35: 245–247.
  14. Kim YH, Prince HM, Whittaker S, et al. BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. Hematological Oncology. 2017; 35: 77–78.



Hematology in Clinical Practice